Abstract
Epileptic encephalopathy is a devastating epilepsy with etiologies that remain largely elusive, despite recent whole-gene/exon sequencing of large cohorts. This study targeted childhood epileptic encephalopathy, typically Lennox-Gastaut syndrome, which is characterized by age-dependent onset and characteristic clinical manifestations. Trio-based whole-exome sequencing was performed in 235 unrelated cases with individualized analysis by explainable inheritance origin with stratified frequency filtration and specified statistical analysis, including setting controls for compound heterozygous variants. We identified three novel causative genes, including SBF1 with de novo variants in three cases, CELSR2 with recessive variants in eight cases, and TENM1 with X-linked recessive variants in six cases. Significantly higher excesses of de novo variants in SBF1 and biallelic variants in CELSR2 and aggregated frequencies of variants in SBF1, CELSR2, and TENM1 were detected. The frequency of compound heterozygous/homozygous CELSR2 variants in the cases was significantly higher than that in 1942 asymptomatic parent controls. In Drosophila, knockdown of the three genes showed increased seizure-like behavior and increased firing of excitatory neurons. Sbf1 knockout zebrafish showed seizure-like behavior, premature death, and increased firing of excitatory neurons. Celsr2 knockout mice showed spontaneous seizures with epileptiform discharges. These results indicate that SBF1, CELSR2, and TENM1 are pathogenic genes of Lennox-Gastaut syndrome.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the National Natural Science Foundation of China (grant Nos. 82171439, 82271505, and 81971216), and Guangdong Basic and Applied Basic Research Foundation (grant No. 2021A1515010986). The funders had no role in study design, data collection, and analysis, or in the decision to publish or the preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All procedures performed were in accordance with the ethical standards of the institutional committee. Ethical approval was approved by the ethics committee of the Second Affiliated Hospital of Guangzhou Medical University (approval ethics number 2020-hs-49).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The article has been polished; Section on discussion has been modified; Figure 2 revised.
Data availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
